Noticed that a few new docs were published on SEDAR on Dec 24 including interim financials and MD&A. Will likely hear about this at the AGM.

A couple of interesting tidbits I noticed through a quick scan.

In April 2015 we selected a new clinical development candidate, and we have completed IND enabling studies. We filed an IND in December 2015 and plan to initiate Phase 1 clinical trials in early calendar 2016. We also continue to progress our preclinical programs, expand our medicinal chemistry operations with leading global contract research organizations, and grow our intellectual property estate.

We are advancing multiple BET inhibitor programs through discovery and early preclinical development that are differentiated from the competing 1st generation BET programs which are in Phase 1 development. These programs provide us with multiple opportunities for developing a best-in-class BET inhibitor with a potential better efficacy and safety profile:
1. Reversible Pan BET inhibitors: These 2nd generation inhibitors, compared to competing BET inhibitors, have shown better preclinical efficacy, better drug like properties, and are not encumbered by any safety issues unlike competing 1st generation BET inhibitors.
2. Covalent BET inhibitors: These inhibitors have sustained effect on cell proliferation and pharmacodynamic modulations compared to reversible inhibitors and have the potential to providing increased efficacy.
3. Bromodomain 1 (“BD1”) selective BET inhibitors: These inhibitors only bind to the BD1 domain of BET proteins and are expected to provide novel biology and the potential for a superior efficacy/safety profile.
In April 2015, we selected a new reversible Pan BET inhibitor clinical development candidate. We completed IND enabling studies and filed an IND in December 2015. In parallel, we have defined our clinical development strategy which will be focused on targeting patient subsets with high unmet need and those that are most likely to benefit from therapy. Zenith will implement a translational medicine approach to our programs as they advance to clinical development.

It looks like we'll have an interesting and perhaps even happy new year ahead of us. GLTA

masila